Figure S4 from Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia

Figure S4: UK5099 does not enhance the efficacy of BETi in preventing MOLM-13 chimerism. NSGS mice were engrafted with MOLM-13 cells and treated with vehicle control, BETi (50 mg/kg) 5 times a week, twice daily and/or UK5099 (40 mg/kg) three times a week, once daily. After 2 wks, peripheral blood (BL), spleen (SPL), and bone marrow (BM) were harvested for chimerism analysis. Each point represents a single mouse (n = 5). Two-way ANOVA with Tukey multiple comparisons test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, ns = not significant).